ADC Toxicity Summit

There is a vast number of ADCs that never make it to the clinic let alone to market, and this is largely due to toxicological challenges providing a narrow therapeutic index. Understanding the causes of toxicity, their translatability into the clinic, as well as mitigation and dosing strategies to limit these toxicities will enable ADC developers to take more assets into the clinic while reducing the costs of failures.

The first-of-its-kind ADC Toxicity Summit will allow companies developing ADCs to overcome toxicological related challenges, by hearing case-study-led presentations on approved ADCs, including ImmunoGen's Mirvetuximab Soravtansine, as well as important scientific and strategic discussions. Designed to provide you with the toolkit to design and deliver more tolerable ADCs to patients without lowering efficacy this is your exclusive opportunity to join peers with expertise in toxicology, safety, and pathology.

The ADC Toxicity Summit is your perfect platform to overcome where others have failed and accelerate more ADCs through preclinical development into the clinic and to market.

URLs:
Website: https://go.evvnt.com/1619266-0?pid=10018
Tickets: https://go.evvnt.com/1619266-1?pid=10018
Brochure: https://go.evvnt.com/1619266-3?pid=10018

Prices:
FULL PACKAGE: Conference + Workshop Day - Drug Developer: USD 4097.00,
Conference Only - Drug Developer: USD 2999.00,
FULL PACKAGE: Conference + Workshop Day - Solution Provider: USD 5297.00,
Conference Only - Solution Provider: USD 3799.00

Speakers: Jennifer Brown, Director - Toxicology, MacroGenics, John Lambert, Independent Consultant, Attager Consulting, Jutta Deckert, Executive Director, Translational Sciences, Iksuda Therapeutics, Lenka Kyrych Sadilkova, Head of Preclinical Research and Development, Mablink, Magali Guffroy, Senior Fellow and Head of Pathology, Preclinical Safety, Research and Oncology, Abbvie, Melanie Frigault, Vice President - Translational Medicine, Vincerx Pharma, Melissa Schutten, Senior Director and Head Of Pathology, Seagen, Mike Seganish, Senior Scientific Director, Merck and Co, Nathan Alves, Director - Translational Research Emergency Medicine, Indiana University School of Medicine, Patrick Zweidler-McKay MD/PhD, Executive Medical Director, ImmunoGen, Rakesh Dixit, President and Chief Executive Officer, Bionavigen, Ronnie Yeager, Project Director/Toxicologist, Emerging Therapeutic Platforms, Abbvie, Sadhna Shankar, Vice President - Clinical Development and Oncology, Eisai, Sayumi Yamazoe, Senior Principal Scientist, Bristol Myers Squibb, Stuart Barnscher, Director - Preclinical Programs, Antibody-drug Conjugate and Therapeutic Development, Zymeworks, Ursula Matulonis, Professor - Medicine, Dana-Farber Cancer Institute